What exactly changed in the Feb 16, 2026 MRNA analyst rating updates?

On February 16, 2026 Citigroup and UBS both maintained **Neutral** ratings for MRNA and raised price targets to **$41** and **$36** respectively, reflecting better forecasts but not a Buy call.

How should investors use the new MRNA price targets?

Compare the **$41** and **$36** targets to the current share price to estimate upside and downside. Use these targets alongside earnings, pipeline updates, and your risk profile to inform position sizing.

Does a maintained Neutral mean the stock is a hold?

Maintained Neutral means the analyst sees neither clear buy nor sell case now. It suggests investors should evaluate fundamentals and catalysts rather than rely solely on the MRNA analyst rating for trading decisions.

How does Meyka AI view these analyst moves?

Meyka AI sees these target increases as evidence of improved expectations but not a shift to consensus Buy. Meyka AI rates MRNA with a grade of **B**, which factors in benchmarks, sector performance, financial growth, metrics, and analyst consensus.

Analyst Ratings

Citigroup and UBS Maintain Neutral on Moderna, Inc. (MRNA) Feb 2026

ByHuzaifa Zahoor February 17, 2026February 17, 2026

Citigroup and UBS on February 16, 2026 maintained Neutral ratings on Moderna, Inc. (MRNA) while raising price targets to $41 and $36 respectively, signaling measured confidence without a full Buy call. The MRNA analyst rating shows price target lifts but no change in conviction. Investors get clearer earnings and pipeline signals, but firms stop short of endorsing a rally. We review each firm’s note, the price targets, market context, and what the MRNA analyst rating means for shareholders and traders.